Ballicules.com

Rosuvastatin

CRESTOR

Pronunciation: roe-soo-va-STAT-in (KRE-stor)

Rosuvastatin ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Rosuvastatin ballicule
Rosuvastatin CRESTOR mascot mnemonic cartoon
Visual mnemonic: Rosuvastatin mascot
“Cresty Roosta-statin”

What it isHMG-CoA reductase inhibitor; high-intensity LDL lowering for hyperlipidemia and ASCVD prevention.

Why this oneVery potent with little CYP3A4 metabolism, making it useful when atorvastatin interactions are problematic.

What limits itRenal impairment and Asian ancestry increase exposure; cyclosporine and gemfibrozil greatly raise myopathy risk.

Rosuvastatin molecular structure (skeletal formula)
Molecular structure: Rosuvastatin

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Hyperlipidemia / mixed dyslipidemia / CV risk reductionAdults5–10 mg QD (per LDL-C and CV risk)per LDL-C goal40 mg QD
Heterozygous familial hypercholesterolemia (HeFH)Pediatric 8–<10 yr5 mg QD—10 mg QD
Heterozygous familial hypercholesterolemia (HeFH)Pediatric >=10 yr5 mg QD—20 mg QD
Homozygous familial hypercholesterolemia (HoFH)Pediatric >=7 yr20 mg QD20 mg QD20 mg QD
Asian patientsAdults5 mg QD—consider risk/benefit above 20 mg QD

Titration Assess LDL-C and adjust dose as early as 4 weeks after initiation.

Renal No adjustment in mild-moderate impairment. Severe (CrCl <30, not on hemodialysis): initiate 5 mg, do not exceed 10 mg QD.

Hepatic Contraindicated in acute liver failure or decompensated cirrhosis.

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Discontinue when pregnancy is recognized; decreases cholesterol synthesis.

Lactation Undefined

Cost

Rosuvastatin (CRESTOR)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
5 mgtab30 qd$0.96offered
10 mgtab30 qd$1.08offered
20 mgtab30 qd$1.36offered
40 mgtab30 qd$2.08offered

Generic entry2016

NO BOXED WARNINGS

Principal riskMyopathy, rarely rhabdomyolysis

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryX

Defining liabilityMyopathy/rhabdomyolysis and hepatotoxicity; interaction burden varies by agent.

Open Rosuvastatin in the interactive console ↗

Memory aids: interaction avatars

Rosuvastatin BCRP substrate avatar mnemonic
BCRP substrate
Rosuvastatin OATP substrate avatar mnemonic
OATP substrate

Open Rosuvastatin in the interactive console ↗